Special Session
Opening Plenary: ASN President's Medal, ASN President's Address, State-of-the-Art Lecture, Featured High-Impact Clinical Trials
October 22, 2026 | 08:00 AM - 09:30 AM
Location: Bluebird Ballroom, Convention Center
Session Description
ASN President's Medal, ASN President's Address, State-of-the-Art Lecture, Featured High-Impact Clinical Trials
Note: Continuing education credits are not being offered for this session.
Support for this session is provided by Vertex Pharmaceuticals.
Learning Objective(s)
- Discuss kidney cure advancements
- Discuss current clinical trials impacting kidney care
- Discuss research on CD19 CAR-T cells
Learning Pathway(s)
- Other
Presentations
-
ASN President's Address
-
ASN President's Medal
-
State-of-the-Art Lecture "Origins and Evolution of CD19 CAR-T Cells"
-
The ORIGIN 3 Trial: Atacicept in IgA Nephropathy
-
Sibeprenlimab in IgA Nephropathy: 24 Months of Data from the Phase 3 VISIONARY Trial
-
Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial